Last $0.0001 USD
Change Today -0.0001 / -50.00%
Volume 2.3M
RXPC On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

radient pharmaceuticals corp (RXPC) Snapshot

Open
$0.0002
Previous Close
$0.0002
Day High
$0.0002
Day Low
$0.0001
52 Week High
02/24/14 - $0.0004
52 Week Low
04/18/13 - $0.0001
Market Cap
134.8K
Average Volume 10 Days
9.1M
EPS TTM
$-12.25
Shares Outstanding
1.3B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RADIENT PHARMACEUTICALS CORP (RXPC)

Related News

No related news articles were found.

radient pharmaceuticals corp (RXPC) Related Businessweek News

No Related Businessweek News Found

radient pharmaceuticals corp (RXPC) Details

Radient Pharmaceuticals Corporation engages in the research, development, manufacture, sale, and marketing of medical diagnostic products. It offers Onko-Sure, a proprietary in-vitro diagnostic cancer test, which is used for the detection and/or monitoring of the presence of colon, rectal, lung, stomach, tongue, ovarian, uterine, liver, pancreatic, bladder, brain, esophageal, hematological, breast, prostate, cervical, thyroid, lymphoma, and trophoblast cancers. The company sells its products through distributors to hospitals, clinical laboratories, clinics, and other health care organizations. It operates primarily in the United States, Canada, China, Chile, Europe, India, Korea, Taiwan, Vietnam, and Japan. The company was formerly known as AMDL, Inc. and changed its name to Radient Pharmaceuticals Corporation in September 2009. Radient Pharmaceuticals Corporation was founded in 1988 and is headquartered in Tustin, California.

11 Employees
Last Reported Date: 06/29/12
Founded in 1988

radient pharmaceuticals corp (RXPC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

radient pharmaceuticals corp (RXPC) Key Developments

The Rosen Law Firm, P.A. Announces Class Action Settlement on Behalf of Purchasers of Common Stock of Radient Pharmaceuticals Corporation

The Rosen Law Firm, P.A. announced that the United States District Court Central District of California Southern Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Radient Pharmaceuticals Corporation. Pursuant to an order of the United States District Court for the Central District of California, that a hearing will be held on April 22, 2014 at 8:30 a.m. before the Honorable David O. Carter, United States District Judge of the Central District of California, 411 West Fourth Street, Santa Ana, California 92701 for the purpose of determining: whether the proposed settlement consisting of the sum of $2,500,000 should be approved by the court as fair, reasonable, and adequate; whether the proposed plan to distribute the settlement proceeds is fair, reasonable, and adequate; whether the application for an award of attorneys' fees of $750,000 or 30.0% and reimbursement of expenses of not more than $480,000, and an incentive payment of no more than $9,000 to lead plaintiffs, should be approved; and whether the litigation should be dismissed with prejudice. If investor purchased common stock of Radient Pharmaceuticals Corporation, during the period between January 18, 2011 and March 4, 2011, inclusive, investor rights may be affected by the Settlement of this action.

Radient Pharmaceuticals Corporation Announces Executive Changes

On June 4, 2013, Mr. Michael Boswell resigned as a member of Radient Pharmaceuticals Corporation's Board of Directors. Mr. Boswell's resignation did not indicate that his resignation was in connection with any disagreement with the Company pertaining to the Company’s operations, policies or practices. Mr. Boswell resigned to dedicate more of his time to his own business and personal pursuits. On June 7, 2013, the Board of Directors appointed Mr. Michael Christiansen to fill the vacancy on Board created by Mr. Boswell's resignation. Mr. Christiansen was formerly the Executive Vice President and Chief Financial Officer of Jameson Stanford Resources Corporation and Bolcán Mining Corporation from May 2012 to November 2012, with his service concluding upon the closing of the merger of the two companies. Prior to joining Bolcán, Mr. Christiansen worked at WestPark Capital from 2007 to 2012 as Managing Director in the Corporate Finance group. Mr. Christiansen has more than fifteen years of investment banking experience, having served previously with Prudential Securities from 1997 to 2001, and with Seidler Amdec Securities and Laffer Associates from 1986 to 1992.

Radient Pharmaceuticals Corporation Enters into 5 Years License Agreement Between AMDL Diagnostics, Inc. and Uni Pharma Co., Ltd

On June 6th 2013, Radient Pharmaceuticals Corporation entered into a 5-year license agreement between AMDL Diagnostics Inc. and Uni Pharma Co. Ltd. with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure® (formerly called DR-70 cancer blood test kits, procedures, analyses, data, know how, manufacturing, manufacturing processes, components, trademarks and intellectual property. Pursuant to the terms of the Agreement, the total license fee shall be $500,000, $100,000 of which UNI shall pay as an up-front license fee ($20,000 upon signing the agreement and $80,000 upon commencement of training UNI personnel at ADI facilities) and the remaining of which, UNI shall pay in 4 equal annual installments over the next 4 years. The license agreement will become effective upon receipt of the up-front license fee. The agreement covers the following territories: China, Hong Kong, Malaysia, Singapore, Indonesia, Thailand, Japan, India, Turkey and Australia and New Zealand. The agreement shall continue until the earlier of expiration of the last patent issued to for the Tests, when UNI terminates the agreement by discontinuing the offering of the Tests, or if UNI does not achieve sales necessary to meet the contractual minimum royalty payments for two consecutive fiscal quarters. Each party has the right to terminate the Agreement in certain circumstances, including a material breach under the Agreement or following a cure period associated with a government imposed prohibition against the sale of the licensed products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXPC:US $0.00 USD -0.0001

RXPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $120.60 USD +0.74
Sigma-Aldrich Corp $94.07 USD +0.05
View Industry Companies
 

Industry Analysis

RXPC

Industry Average

Valuation RXPC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RADIENT PHARMACEUTICALS CORP, please visit www.radient-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.